These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1137 related items for PubMed ID: 23213945

  • 1. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 3. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Jun; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 6. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 7. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 8. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [Abstract] [Full Text] [Related]

  • 9. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 10. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST, Gotlib J.
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [Abstract] [Full Text] [Related]

  • 11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 12. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.
    Kurume Med J; 2014 Sep; 60(3-4):89-97. PubMed ID: 24858412
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
    Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, Saxena R.
    Indian J Med Res; 2010 Oct; 132():423-7. PubMed ID: 20966521
    [Abstract] [Full Text] [Related]

  • 14. JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation.
    Sassi H, Menif S, Ammar SB, Farrah A, Othmen HBH, Amouri H.
    Pan Afr Med J; 2021 Oct; 39():194. PubMed ID: 34603575
    [Abstract] [Full Text] [Related]

  • 15. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 16. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 17. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 18. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA, Smith-Gagen JA.
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [Abstract] [Full Text] [Related]

  • 19. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 20. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N.
    Br J Haematol; 2007 Oct 20; 139(1):64-9. PubMed ID: 17854308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.